共 50 条
Albuminuria and Heart Failure JACC State-of-the-Art Review
被引:46
|作者:
Khan, Muhammad Shahzeb
[1
]
Shahid, Izza
[2
]
Anker, Stefan D.
[3
]
Fonarow, Gregg C.
[4
]
Fudim, Marat
[1
,5
]
Hall, Michael E.
[6
]
Hernandez, Adrian
[1
,5
]
Morris, Alanna A.
[7
]
Shafi, Tariq
[8
]
Weir, Matthew R.
[9
]
Zannad, Faiez
[10
]
Bakris, George L.
[11
]
Butler, Javed
[6
,12
,13
]
机构:
[1] Duke Univ, Div Cardiol, Sch Med, Durham, NC USA
[2] Houston Methodist Acad Inst, Dept Cardiol, Div Prevent Cardiol, Houston, TX USA
[3] Charite Univ Med Berlin, German Ctr Cardiovasc Res, Dept Cardiol CVK, Berlin Inst Hlth Ctr Regenerat Therapies, Berlin, Germany
[4] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA
[5] Duke Clin Res Inst, Durham, NC USA
[6] Univ Mississippi, Dept Med, Med Ctr, Jackson, MS USA
[7] Emory Univ, Div Cardiol, Atlanta, GA USA
[8] Univ Mississippi, Div Nephrol, Med Ctr, Jackson, MS USA
[9] Univ Maryland, Div Nephrol, Sch Med, Baltimore, MD USA
[10] Univ Lorraine, CIC Inserm, CHRU, Nancy, France
[11] Univ Chicago Med, Dept Med, Chicago, IL USA
[12] Baylor Scott & White Res Inst, Dallas, TX USA
[13] Baylor Scott & White Res Inst, 3434 Oak St,Ste 501, Dallas, TX 75204 USA
基金:
美国国家卫生研究院;
美国医疗保健研究与质量局;
关键词:
albuminuria;
clinical trials;
heart failure;
CHRONIC KIDNEY-DISEASE;
PRESERVED EJECTION FRACTION;
GLOMERULAR-FILTRATION-RATE;
COMMUNITY-BASED COHORT;
LOW-GRADE ALBUMINURIA;
URINARY ALBUMIN;
RENAL-FUNCTION;
CARDIOVASCULAR MORTALITY;
DIABETIC-PATIENTS;
ALL-CAUSE;
D O I:
10.1016/j.jacc.2022.10.028
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Although chronic kidney disease is characterized by low glomerular filtration rate (GFR) or albuminuria, estimated GFR (eGFR) is more widely utilized as a marker of risk profile in cardiovascular diseases, including heart failure (HF). The presence and magnitude of albuminuria confers a strong prognostic association in forecasting risk of incident HF as well as its progression, irrespective of eGFR. Despite the high prevalence of albuminuria in HF, whether it adds incremental prognostic information in clinical practice and serves as an independent risk marker, and whether there are any therapeutic implications of assessing albuminuria in patients with HF is less well-established. In this narrative review, we assess the potential role of albuminuria in risk profiling for development and progression of HF, strengths and limitations of utilizing albuminuria as a risk marker, its ability to serve in HF risk prediction models, and the implications of adopting albuminuria as an effective parameter in cardiovascular trials and practice. (J Am Coll Cardiol 2023;81:270-282) (c) 2023 by the American College of Cardiology Foundation.
引用
收藏
页码:270 / 282
页数:13
相关论文